Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369]

Draft guidance

Draft consultation document (online commenting)

Draft consultation document (downloadable version) (PDF 277 KB)

Committee papers (PDF 14.21 MB)

Public committee slides (PDF 1.49 MB)

Assessment report (PDF 9.54 MB)

Draft scope and provisional stakeholder list comments table (post-referral) (MSWord 96 KB)

Equality impact assessment (Scoping) (MSWord 23 KB)

Provisional Stakeholder List (post-referral) (MSWord 30 KB)

Final scope (MSWord 39 KB)

Draft matrix post referral (PDF 171 KB)